Treatment of Mast Cell Activation with Leukopenia

Core Anti-Mediator Therapy

The National Comprehensive Cancer Network recommends anti-mediator therapy with H1 and H2 antihistamines and mast cell stabilizers as the primary treatment for mast cell activation symptoms, regardless of white blood cell count, to address the underlying pathophysiology of mast cell mediator release 1, 2
H1 antihistamines, such as cetirizine or fexofenadine, should be initiated at 2-4 times FDA-approved doses to reduce inflammation and symptoms in patients with mast cell activation 3
H2 antihistamines, such as famotidine, should be added to enhance symptom control by blocking additional histamine pathways in patients with mast cell activation 3

For patients with advanced systemic mastocytosis on midostaurin who develop leukopenia, the National Comprehensive Cancer Network recommends interrupting midostaurin if ANC falls below 1 × 10⁹/L, and resuming at a reduced dose once ANC recovers above 1 × 10⁹/L 1
The National Comprehensive Cancer Network suggests discontinuing midostaurin if low ANC persists for more than 21 days and is suspected to be drug-related in patients with advanced systemic mastocytosis 1
For patients with mast cell activation and leukopenia not on cytoreductive agents, the National Comprehensive Cancer Network recommends continuing anti-mediator therapy, as the leukopenia is likely unrelated to mast cell activation treatment, and investigating other causes of leukopenia 2, 4

The National Comprehensive Cancer Network suggests adding leukotriene modifiers, such as montelukast or zileuton, if urinary LTE4 levels are elevated or response to antihistamines is inadequate in patients with mast cell activation 3
Aspirin therapy may be beneficial if prostaglandin levels are elevated, but should be used with caution as it can trigger mast cell activation in some patients with mast cell activation 3
Avoiding known triggers of mast cell activation, including certain medications, temperature extremes, and physical trauma, is recommended for patients with mast cell activation 5

The National Comprehensive Cancer Network recommends that all patients with mast cell activation carry two epinephrine auto-injectors at all times to manage anaphylaxis, which occurs more frequently in these patients 2
Patients with mast cell activation should receive premedication with antihistamines and corticosteroids before invasive procedures, surgery, or endoscopy to prevent anaphylaxis 1, 2
Having emergency medications readily available, such as epinephrine, corticosteroids, and additional antihistamines, during any medical interventions is crucial for patients with mast cell activation 5

Pain management requires special attention, and while opioids like morphine and codeine should be used with caution due to potential mast cell triggering, they should never be withheld when needed, as pain itself can trigger mast cell degranulation in patients with mast cell activation 1, 5
Fentanyl and remifentanil are safer opioid alternatives for patients with mast cell activation 1, 5
Referral to specialized centers with expertise in mastocytosis is strongly recommended for optimal management, particularly when dealing with complex presentations involving cytopenias in patients with mast cell activation 2, 4